APS vs. BCT, HBP, IBT, ACST, GSD, LTY, CZO, SBM, REUN, and KNE
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include BriaCell Therapeutics (BCT), Helix BioPharma (HBP), IBEX Technologies (IBT), Acasti Pharma (ACST), Devonian Health Group (GSD), Liberty Biopharma (LTY), Ceapro (CZO), Sirona Biochem (SBM), Reunion Neuroscience (REUN), and Kane Biotech (KNE). These companies are all part of the "biotechnology" industry.
Aptose Biosciences vs.
BriaCell Therapeutics (TSE:BCT) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
15.0% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Aptose Biosciences shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
BriaCell Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.
BriaCell Therapeutics' return on equity of -206.01% beat Aptose Biosciences' return on equity.
Aptose Biosciences received 211 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 72.11% of users gave Aptose Biosciences an outperform vote.
BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, BriaCell Therapeutics had 2 more articles in the media than Aptose Biosciences. MarketBeat recorded 2 mentions for BriaCell Therapeutics and 0 mentions for Aptose Biosciences. BriaCell Therapeutics' average media sentiment score of 3.00 beat Aptose Biosciences' score of 0.00 indicating that BriaCell Therapeutics is being referred to more favorably in the media.
Summary
BriaCell Therapeutics beats Aptose Biosciences on 8 of the 12 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
This page (TSE:APS) was last updated on 11/5/2024 by MarketBeat.com Staff
